Two Sigma Securities LLC Has $599,000 Holdings in DexCom, Inc. $DXCM

Two Sigma Securities LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 173.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,895 shares of the medical device company’s stock after acquiring an additional 5,644 shares during the quarter. Two Sigma Securities LLC’s holdings in DexCom were worth $599,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB raised its holdings in shares of DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after purchasing an additional 153 shares during the period. V Square Quantitative Management LLC increased its stake in DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares during the last quarter. Essex Financial Services Inc. lifted its holdings in DexCom by 5.7% during the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after acquiring an additional 175 shares during the period. Keel Point LLC boosted its position in DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after purchasing an additional 193 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its position in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the sale, the executive vice president directly owned 126,043 shares in the company, valued at $11,138,419.91. This represents a 1.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 70,688 shares of company stock valued at $5,314,766 in the last 90 days. Insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $90.14 on Wednesday. The stock has a market capitalization of $34.02 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 1.54 and a beta of 1.42. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The business’s 50 day simple moving average is $80.07 and its two-hundred day simple moving average is $71.93.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the business posted $0.48 earnings per share. DexCom’s revenue for the quarter was up 13.1% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Citigroup reissued a “buy” rating and issued a $88.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Weiss Ratings upgraded DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Benchmark increased their price target on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $94.00 price target on shares of DexCom in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.